John S P Yuen1, Valentine M Macaulay. 1. Weatherall Institute of Molecular Medicine, University of Oxford, IGF Group, Molecular Oncology Laboratories, Headley Way, Headington, Oxford OX3 9DS, UK.
Abstract
BACKGROUND: The type 1 insulin-like growth factor receptor (IGF1R) plays a critical role in transformation, invasion and apoptosis protection, and is an attractive cancer treatment target. OBJECTIVE: To review IGF1R antibodies and kinase inhibitors that are in preclinical and clinical development, and to discuss questions that will influence the success of this approach in clinical practice. METHODS: This review is drawn from published literature, meeting abstracts and online resources. RESULTS/ CONCLUSION: IGF1R blockade is generally well tolerated although it can induce hyperglycaemia. Single-agent activity has been documented in Ewing's sarcoma but not thus far in common solid tumours. Key issues include identification of factors that influence sensitivity to IGF1R blockade, and how most effectively to combine IGF1R inhibitors with other treatments.
BACKGROUND: The type 1 insulin-like growth factor receptor (IGF1R) plays a critical role in transformation, invasion and apoptosis protection, and is an attractive cancer treatment target. OBJECTIVE: To review IGF1R antibodies and kinase inhibitors that are in preclinical and clinical development, and to discuss questions that will influence the success of this approach in clinical practice. METHODS: This review is drawn from published literature, meeting abstracts and online resources. RESULTS/ CONCLUSION:IGF1R blockade is generally well tolerated although it can induce hyperglycaemia. Single-agent activity has been documented in Ewing's sarcoma but not thus far in common solid tumours. Key issues include identification of factors that influence sensitivity to IGF1R blockade, and how most effectively to combine IGF1R inhibitors with other treatments.
Authors: William Engen; Terrence E O'Brien; Brendan Kelly; Jacinda Do; Liezel Rillera; Lance K Stapleton; Jack F Youngren; Marc O Anderson Journal: Bioorg Med Chem Date: 2010-06-25 Impact factor: 3.641
Authors: Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead Journal: Neoplasia Date: 2009-07 Impact factor: 5.715
Authors: Qianghua Hu; Fei Gao; Weihua Tian; E Cristy Ruteshouser; Yaqing Wang; Alexander Lazar; John Stewart; Louise C Strong; Richard R Behringer; Vicki Huff Journal: J Clin Invest Date: 2010-12-01 Impact factor: 14.808
Authors: Katinka Rüping; Annelore Altendorf-Hofmann; Yuan Chen; Eric Kampmann; Sebastian Gibis; Lars Lindner; Detlef Katenkamp; Iver Petersen; Thomas Knösel Journal: J Cancer Res Clin Oncol Date: 2014-05-08 Impact factor: 4.553
Authors: Panagiotis A Konstantinopoulos; Elena Fountzilas; Jeffrey D Goldsmith; Manoj Bhasin; Kamana Pillay; Nancy Francoeur; Towia A Libermann; Mark C Gebhardt; Dimitrios Spentzos Journal: PLoS One Date: 2010-04-01 Impact factor: 3.240